Metsera, Inc. is a clinical-stage biopharmaceutical company, which is developing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies. The Company uses its proprietary MINT peptide library of nutrient stimulated hormone (NuSH) analog peptides alongside its half-life augmentation by lipid optimization (HALO) half-life extending platform and its MOMENTUM oral NuSH analog peptide delivery platform to deliver differentiated product candidates. Its product pipeline includes MET-097i, MET-233i, MET-233i + MET-097i, MET-097o/MET-224o, MET-002o, MET-034i, MET-067i, and MET-815i. The Company's additional pipeline includes MET-815i, MET-AMYo, MET-034i, MET-067i and MET-PYYi. MET-097i, its advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA. MET-233i is a subcutaneously injectable ultra-long-acting amylin analog, with enhanced solubility and miscibility with its other NuSH analog peptides.
종목 코드 MTSR
회사 이름Metsera Inc
상장일Jan 31, 2025
CEOMr. Christopher Whitten Bernard
직원 수74
유형Ordinary Share
회계 연도 종료Jan 31
주소3 World Trade Center
도시NEW YORK
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호10007
전화12127846595
웹사이트https://metsera.com/
종목 코드 MTSR
상장일Jan 31, 2025
CEOMr. Christopher Whitten Bernard
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음